Get the Stockscreener App
2.20
2.22%
-0.05
Alzamend Neuro Inc stock is traded at $2.20, with a volume of 101.84K.
It is down -2.22% in the last 24 hours and down -24.66% over the past month.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
See More
Previous Close:
$2.25
Open:
$2.11
24h Volume:
101.84K
Relative Volume:
0.07
Market Cap:
$6.37M
Revenue:
-
Net Income/Loss:
$-5.85M
P/E Ratio:
-0.329
EPS:
-6.6877
Net Cash Flow:
$-8.00M
1W Performance:
-25.68%
1M Performance:
-24.66%
6M Performance:
-78.46%
1Y Performance:
-93.05%
1-Day Range:
$2.06
$2.2809
1-Week Range:
$2.06
$2.89
52-Week Range:
$2.06
$135.54
Alzamend Neuro Inc Stock (ALZN) Company Profile
Name
Alzamend Neuro Inc
Sector
Industry
Phone
844-722-6333
Address
3500 LENOX RD. NE, ATLANTA
Compare ALZN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALZN
Alzamend Neuro Inc
|
2.20 | 6.52M | 0 | -5.85M | -8.00M | -6.6877 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Alzamend Neuro Inc Stock (ALZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-01-21 | Initiated | Ascendiant Capital Markets | Buy |
Alzamend Neuro Inc Stock (ALZN) Latest News
Alzamend Neuro Inc. stock volume spike explainedHistorical Volatility and Pattern Breakdown Analysis - Newser
How Alzamend Neuro Inc. stock performs during market volatilityFree Real Time Stock Movement Analysis - Newser
Alzamend Neuro Increases Common Stock Through Conversion - TipRanks
Technical analysis overview for Alzamend Neuro Inc. stockDaily Profit Watch With Forecast Confidence - Newser
Forecasting Alzamend Neuro Inc. price range with options dataSector-Wise Stock Strength Trend Analysis - Newser
What is the dividend policy of Alzamend Neuro Inc. stockMarket Forecast Picks That Work - jammulinksnews.com
How does Alzamend Neuro Inc. compare to its industry peersWealth Building Target Finder To Watch Now - jammulinksnews.com
Should I hold or sell Alzamend Neuro Inc. stock in 2025Pre Market Forecasts For Smart Trading - jammulinksnews.com
Why Alzamend Neuro Inc. stock attracts strong analyst attentionEarnings Report Summary with Market Impact - Newser
What makes Alzamend Neuro Inc. stock price move sharplyRetirement Investment Outlook and Return Summary - Newser
Analyzing Alzamend Neuro Inc. with multi timeframe chartsWatchlist Generator With Real-Time Entry - Newser
Alzamend Neuro Director Sells Thousands of Shares Amidst Positive Market Sentiment - AInvest
New Product Launches: Will They Boost Alzamend Neuro Inc. Stock in 2025Entry Plan for Oversold Reversal Stocks Released - metal.it
Alzamend Neuro to Present at the 2025 Military Health System Research Symposium - BioSpace
Alzamend Neuro Inc. Shows Support at Fibonacci LevelAI Powered High Return Stock Calls Dominate Watchlists - metal.it
Military PTSD Breakthrough: Alzamend Reveals New Lithium Treatment Data at Defense Health Summit - Stock Titan
Why is Alzamend Neuro Inc. stock attracting strong analyst attentionSkyrocketing returns - jammulinksnews.com
Is Alzamend Neuro Inc. stock overvalued or undervaluedUnlock daily stock market insights for success - jammulinksnews.com
What institutional investors are buying Alzamend Neuro Inc. stockExceptional stock performance - jammulinksnews.com
What are the technical indicators suggesting about Alzamend Neuro Inc.Market-crushing profits - jammulinksnews.com
How does Alzamend Neuro Inc. generate profit in a changing economyMaximize portfolio value with smart investment plans - jammulinksnews.com
When is Alzamend Neuro Inc. stock expected to show significant growthConsistent high-performance stocks - jammulinksnews.com
Is Alzamend Neuro Inc. a growth stock or a value stockUnlock exclusive trading tools and resources - jammulinksnews.com
Published on: 2025-07-27 16:38:55 - jammulinksnews.com
Alzamend Neuro (ALZN) to Release Earnings on Tuesday - Defense World
Is Alzamend Neuro Inc. stock a growth or value playSuperior stock growth - jammulinksnews.com
Is Alzamend Neuro Inc. a good long term investmentSkyrocketing profit margins - PrintWeekIndia
Alzamend Neuro Inc. Stock Analysis and ForecastFree Stock Market Trend Analysis - PrintWeekIndia
Will Alzamend Neuro Inc. stock benefit from AI tech trendsAccelerated profit realization - jammulinksnews.com
What drives Alzamend Neuro Inc. stock priceUnprecedented profits - PrintWeekIndia
Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs - The Manila Times
Alzamend Kicks Off Groundbreaking Lithium Brain Studies at Mass General While Securing $10.4M Financial Boost - Stock Titan
What analysts say about Alzamend Neuro Inc. stockHigh-yield market plays - Autocar Professional
Alzamend Neuro Inc Stock (ALZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alzamend Neuro Inc Stock (ALZN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| AULT MILTON C III | Director |
Jul 30 '25 |
Sale |
2.51 |
29,449 |
73,982 |
108,260 |
| AULT MILTON C III | Director |
Jul 25 '25 |
Sale |
2.90 |
36,532 |
105,855 |
46,020 |
| AULT MILTON C III | Director |
Jul 28 '25 |
Sale |
2.68 |
8,311 |
22,314 |
37,709 |
| AULT MILTON C III | Director |
Jul 23 '25 |
Sale |
2.95 |
59,516 |
175,584 |
92,173 |
| AULT MILTON C III | Director |
Jul 24 '25 |
Sale |
2.93 |
9,621 |
28,237 |
82,552 |
| AULT MILTON C III | Director |
May 12 '25 |
Sale |
5.06 |
1,213 |
6,138 |
8,260 |
| AULT MILTON C III | Director |
May 12 '25 |
Sale |
5.28 |
11 |
58 |
1,843 |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):